Connection

William Hrushesky to Male

This is a "connection" page, showing publications William Hrushesky has written about Male.
Connection Strength

0.353
  1. The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer. BMC Cancer. 2011 May 23; 11:193.
    View in: PubMed
    Score: 0.020
  2. Sunspot dynamics are reflected in human physiology and pathophysiology. Astrobiology. 2011 Mar; 11(2):93-103.
    View in: PubMed
    Score: 0.020
  3. Actigraphic assessment of daily sleep-activity pattern abnormalities reflects self-assessed depression and anxiety in outpatients with advanced non-small cell lung cancer. Psychooncology. 2010 Feb; 19(2):180-9.
    View in: PubMed
    Score: 0.019
  4. Circadian disruption, Per3, and human cytokine secretion. Integr Cancer Ther. 2009 Dec; 8(4):329-36.
    View in: PubMed
    Score: 0.018
  5. Developmental abnormalities in multiple proliferative tissues of Apc(Min/+) mice. Int J Exp Pathol. 2006 Jun; 87(3):227-36.
    View in: PubMed
    Score: 0.014
  6. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer. 2005 Nov 28; 93(11):1202-8.
    View in: PubMed
    Score: 0.014
  7. Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Mol Cancer Ther. 2005 Jul; 4(7):1065-75.
    View in: PubMed
    Score: 0.013
  8. Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther. 2003 Jun; 2(2):105-11.
    View in: PubMed
    Score: 0.012
  9. Androgen suppression and irradiation for locally advanced prostate cancer. Lancet. 2002 Dec 14; 360(9349):1987; author reply 1987-8.
    View in: PubMed
    Score: 0.011
  10. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
    View in: PubMed
    Score: 0.010
  11. Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2000 Mar 01; 46(4):873-81.
    View in: PubMed
    Score: 0.009
  12. End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
    View in: PubMed
    Score: 0.009
  13. Fertility maintenance and 5-fluorouracil timing within the mammalian fertility cycle. Reprod Toxicol. 1999 Sep-Oct; 13(5):413-20.
    View in: PubMed
    Score: 0.009
  14. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
    View in: PubMed
    Score: 0.008
  15. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. Br J Haematol. 2018 01; 180(2):301-304.
    View in: PubMed
    Score: 0.007
  16. Adding Bevacizumab to the Treatment of Patients With Non-Small-Cell Lung Cancer: Caveat Emptor. J Oncol Pract. 2015 Sep; 11(5):363-4.
    View in: PubMed
    Score: 0.007
  17. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995 Apr; 95(4):1650-9.
    View in: PubMed
    Score: 0.007
  18. The Department of Veterans Affairs' unique clinical cancer research effort. Cancer. 1994 Nov 01; 74(9 Suppl):2701-9.
    View in: PubMed
    Score: 0.006
  19. Circadian cancer pharmacodynamics. Ann Ist Super Sanita. 1993; 29(4):705-10.
    View in: PubMed
    Score: 0.006
  20. Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. Circulation. 1991 Aug; 84(2):697-707.
    View in: PubMed
    Score: 0.005
  21. Quantitative respiratory sinus arrhythmia analysis. A simple noninvasive, reimbursable measure of cardiac wellness and dysfunction. Ann N Y Acad Sci. 1991; 618:67-101.
    View in: PubMed
    Score: 0.005
  22. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol. 1990 Sep; 8(9):1504-13.
    View in: PubMed
    Score: 0.005
  23. Health care for US veterans and others. Lancet. 1990 Jul 21; 336(8708):182.
    View in: PubMed
    Score: 0.005
  24. Pharmacodynamics of local heparin infusion in a canine renal allograft model. J Pharmacol Exp Ther. 1990 Feb; 252(2):733-8.
    View in: PubMed
    Score: 0.005
  25. Enhancement of respiratory sinus arrhythmia by moderate exercise. Prog Clin Biol Res. 1990; 341A:283-96.
    View in: PubMed
    Score: 0.005
  26. Oral temperature rhythmometry and substantial within-day variation in zidovudine levels following steady-state dosing in human immunodeficiency virus (HIV) infection. Prog Clin Biol Res. 1990; 341A:67-76.
    View in: PubMed
    Score: 0.005
  27. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol. 1989 Nov; 7(11):1710-9.
    View in: PubMed
    Score: 0.005
  28. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst. 1989 Jan 18; 81(2):135-45.
    View in: PubMed
    Score: 0.004
  29. A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. Clin Colorectal Cancer. 2008 Mar; 7(2):134-9.
    View in: PubMed
    Score: 0.004
  30. Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion. J Urol. 1988 Feb; 139(2):259-62.
    View in: PubMed
    Score: 0.004
  31. Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. Semin Surg Oncol. 1988; 4(2):110-5.
    View in: PubMed
    Score: 0.004
  32. Circadian susceptibility-resistance cycles to radiation and their manipulability by methylene blue. Pharmacol Ther. 1988; 39(1-3):397-402.
    View in: PubMed
    Score: 0.004
  33. High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer. Cancer Treat Rep. 1987 Oct; 71(10):915-9.
    View in: PubMed
    Score: 0.004
  34. High-dose intensity systemic therapy of metastatic bladder cancer. J Clin Oncol. 1987 Mar; 5(3):450-5.
    View in: PubMed
    Score: 0.004
  35. Advanced transitional cell bladder cancer: a treatable disease. Semin Surg Oncol. 1986; 2(2):76-89.
    View in: PubMed
    Score: 0.003
  36. Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences. Chronobiol Int. 1986; 3(1):55-64.
    View in: PubMed
    Score: 0.003
  37. Lack of antiemetic effect of high-dose metoclopramide. J Clin Oncol. 1985 Sep; 3(9):1273-6.
    View in: PubMed
    Score: 0.003
  38. Circadian toxicology of cyclosporin. Toxicol Appl Pharmacol. 1985 Jan; 77(1):181-5.
    View in: PubMed
    Score: 0.003
  39. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005 Jan; 41(1):88-96.
    View in: PubMed
    Score: 0.003
  40. 24-hour mean pulse. Simple predictor of doxorubicin-induced cardiac damage. Am J Med. 1984 Sep; 77(3):399-406.
    View in: PubMed
    Score: 0.003
  41. The respiratory sinus arrhythmia: a measure of cardiac age. Science. 1984 Jun 01; 224(4652):1001-4.
    View in: PubMed
    Score: 0.003
  42. Lack of age-dependent cisplatin nephrotoxicity. Am J Med. 1984 Apr; 76(4):579-84.
    View in: PubMed
    Score: 0.003
  43. Circadian mesor of recumbent pulse--cost-effective predictor of doxorubicin-induced congestive heart failure. Chronobiol Int. 1984; 1(1):59-66.
    View in: PubMed
    Score: 0.003
  44. Circadian rhythmicity of polyamine urinary excretion. Cancer Res. 1983 Aug; 43(8):3944-7.
    View in: PubMed
    Score: 0.003
  45. Circadian time dependence of cisplatin urinary kinetics. Clin Pharmacol Ther. 1982 Sep; 32(3):330-9.
    View in: PubMed
    Score: 0.003
  46. Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res. 2001 Mar; 92(3):328-36.
    View in: PubMed
    Score: 0.002
  47. Unusual pigmentary changes associated with 5-fluorouracil therapy. Cutis. 1980 Aug; 26(2):181-82.
    View in: PubMed
    Score: 0.002
  48. Subcutaneous heparin-induced thrombocytopenia. Arch Intern Med. 1978 Oct; 138(10):1489-91.
    View in: PubMed
    Score: 0.002
  49. Thrombocytopenia induced by low-dose subcutaneous heparin. Lancet. 1977 Dec 17; 2(8051):1286.
    View in: PubMed
    Score: 0.002
  50. Current status of the therapy of advanced renal carcinoma. J Surg Oncol. 1977; 9(3):277-88.
    View in: PubMed
    Score: 0.002
  51. Letter: Serpentine supravenous fluorouracil hyperpigmentation. JAMA. 1976 Jul 12; 236(2):138.
    View in: PubMed
    Score: 0.002
  52. Serpentine supravenous 5-fluorouracil (NSC-19893) hyperpigmentation. Cancer Treat Rep. 1976 May; 60(5):639.
    View in: PubMed
    Score: 0.002
  53. Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. A report of three cases. Cancer. 1995 May 15; 75(10):2558-64.
    View in: PubMed
    Score: 0.002
  54. Evaluation of chemotherapeutic agents in a new murine renal carcinoma model. J Natl Cancer Inst. 1974 Apr; 52(4):1117-22.
    View in: PubMed
    Score: 0.002
  55. A murine renal cell carcinoma. J Natl Cancer Inst. 1973 Apr; 50(4):1013-25.
    View in: PubMed
    Score: 0.001
  56. Carcinogenicity of ethylmethanesulfonate. J Natl Cancer Inst. 1972 Oct; 49(4):1077-83.
    View in: PubMed
    Score: 0.001
  57. Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local immunosuppression. Transplantation. 1992 Jan; 53(1):12-9.
    View in: PubMed
    Score: 0.001
  58. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology. 1991 Aug; 101(2):410-5.
    View in: PubMed
    Score: 0.001
  59. Circadian rhythm alteration in HIV infected subjects. Prog Clin Biol Res. 1990; 341A:437-49.
    View in: PubMed
    Score: 0.001
  60. Local immunosuppression with reduced systemic toxicity in a canine renal allograft model. Transplantation. 1989 Dec; 48(6):936-43.
    View in: PubMed
    Score: 0.001
  61. Feasibility of vascular catheter placement for intrarenal infusion in a canine autotransplant model. Transplant Proc. 1989 Feb; 21(1 Pt 1):1125-6.
    View in: PubMed
    Score: 0.001
  62. The chronopharmacokinetics of cyclosporine and its metabolites in recipients of pancreas allografts. Transplant Proc. 1988 Apr; 20(2 Suppl 2):471-7.
    View in: PubMed
    Score: 0.001
  63. Circadian characteristics of dialyzable and non-dialyzable human urinary electrolytes, trace elements and total solids. Chronobiol Int. 1988; 5(2):175-84.
    View in: PubMed
    Score: 0.001
  64. [Biological rhythms and tumor markers in man. With special reference to the carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP) in digestive system tumors]. Acta Gastroenterol Belg. 1987 Jan-Feb; 50(1):12-21.
    View in: PubMed
    Score: 0.001
  65. Hormonal and chemotherapeutic treatment of prostatic carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen-Fischer rats. Oncology. 1985; 42(1):48-54.
    View in: PubMed
    Score: 0.001
  66. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984 Jul; 34(7):934-8.
    View in: PubMed
    Score: 0.001
  67. Time-varying effects in mice and rats of several synthetic ACTH preparations. Chronobiologia. 1980 Apr-Jun; 7(2):211-26.
    View in: PubMed
    Score: 0.001
  68. Synthetic adrenocorticotropin for optimizing murine circadian chronotolerance for adriamycin. Chronobiologia. 1980 Apr-Jun; 7(2):227-44.
    View in: PubMed
    Score: 0.001
  69. Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: response to chemotherapy in two cases. Med Pediatr Oncol. 1979; 7(2):111-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.